ArticleNature genetics2022
CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk.
Open access · greenAbstract read
In one paragraph
Article in Nature genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Revisiting KIR restriction and CD94 expression in diagnostic criteria for NK-large granular lymphocytic leukemia.Blood advances · 2026Article
- Transcriptomic Analysis of Tendon Healing Using an Extracellular Matrix-Coated, Polyurethane Scaffold.Bioengineering (Basel, Switzerland) · 2026Article
- Diagnostic criteria for NK cell large granular lymphocyte leukemia: validation through a multicentric international study.Blood advances · 2026Article
- Extensive but Steroid-sensitive Pulmonary Infiltration by Natural Killer-large Granular Lymphocytic Leukemia.Internal medicine (Tokyo, Japan) · 2025Article
- Encoding and decoding selectivity and promiscuity in the human chemokine-GPCR interaction network.Cell · 2025Article
- NK-type large granular lymphocyte leukemia comes of age.HemaSphere · 2025Review
- Inborn errors of immunity underlie clonal T cell expansions in large granular lymphocyte leukemia.The Journal of clinical investigation · 2025Article
- Classification of NK-large granular lymphocytic leukemia by CD56 expression.The oncologist · 2025Article
- Clonal hematopoiesis in large granular lymphocytic leukemia.Leukemia · 2025Article
- Large granular lymphocyte leukemia: a clonal disorder with autoimmune manifestations.Hematology. American Society of Hematology. Education Program · 2024Review
- Clinical Significance of Combined Detection of CCL22 and IL-1 as Potential New Bronchial Inflammatory Mediators in Children's Asthma.Immunity, inflammation and disease · 2024Article
- Article
- Article
- KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma Subtypes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Analysis of somatic mutations in whole blood from 200,618 individuals identifies pervasive positive selection and novel drivers of clonal hematopoiesis.Nature genetics · 2024Article
- ActivatingFrontiers in immunology · 2024Article
- Review
- The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives.Experimental hematology & oncology · 2023Review
- IsoAnalytics: a single-cell proteomics web server.Bioinformatics advances · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 6 institutions in 2 countries.
Constance Baer *MLL Munich Leukemia Laboratory, Munich, Germany.
Shunsuke Kimura *Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA. shunsuke.kimura@stjude.org.ORCID http://orcid.org/0000-0002-2158-467X
Mitra S RanaProtein Technologies Center, Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0002-0915-8141
Andrew B KleistDepartment of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, USA.
Tim FlerlageDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.
David J FeithUniversity of Virginia Cancer Center, Charlottesville, VA, USA.ORCID http://orcid.org/0000-0003-4981-1691
Peter ChockleyDepartment of Bone Marrow Transplantation & Cell Therapy, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0002-5181-2696
Wencke WalterMLL Munich Leukemia Laboratory, Munich, Germany.ORCID http://orcid.org/0000-0002-5083-9838
Manja MeggendorferMLL Munich Leukemia Laboratory, Munich, Germany.
Thomas L OlsonUniversity of Virginia Cancer Center, Charlottesville, VA, USA.
HeeJin CheonUniversity of Virginia Cancer Center, Charlottesville, VA, USA.
Kristine C OlsonUniversity of Virginia Cancer Center, Charlottesville, VA, USA.
Aakrosh RatanUniversity of Virginia Cancer Center, Charlottesville, VA, USA.ORCID http://orcid.org/0000-0002-0782-3056
Martha-Lena MuellerMLL Munich Leukemia Laboratory, Munich, Germany.
James M ForanCenter for Public Health Genomics, University of Virginia, Charlottesville, VA, USA.
Laura J JankeDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Chunxu QuDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Shaina N PorterDepartment of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Shondra M Pruett-MillerDepartment of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0002-3793-585X
Ravi C KalathurProtein Technologies Center, Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0002-4889-8003
Claudia HaferlachMLL Munich Leukemia Laboratory, Munich, Germany.
Wolfgang KernMLL Munich Leukemia Laboratory, Munich, Germany.
Elisabeth PaiettaDepartment of Oncology, Montefiore Medical Center, Bronx, NY, USA.
Paul G ThomasDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0001-7955-0256
M Madan BabuCenter of Excellence for Data Driven Discovery, Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0003-0556-6196
Thomas P LoughranUniversity of Virginia Cancer Center, Charlottesville, VA, USA.
Ilaria IacobucciDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA. ilaria.iacobucci@stjude.org.ORCID http://orcid.org/0000-0003-2008-1365
Torsten HaferlachMLL Munich Leukemia Laboratory, Munich, Germany. torsten.haferlach@mll.com.ORCID http://orcid.org/0000-0003-0196-2837
Charles G MullighanDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA. charles.mullighan@stjude.org.ORCID http://orcid.org/0000-0002-1871-1850
St. Jude Children's Research Hospital · USMunich Leukemia Laboratory (Germany) · DEUniversity of Virginia Cancer CenterMedical College of Wisconsin · USMontefiore Medical Center · USUniversity of Virginia · US
Funding
Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6MViral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Shondra Michelle Miller · 1985 to 2026
$166.9MWomen's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Dina Gould Halme · 1987 to 2026
$72.1MECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · 2015 to 2026
$41.1MBASIC CARDIOVASCULAR RESEARCH TRAINING GRANTT32HL007284 · NHLBI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Brant E Isakson, Gary K Owens · 1985 to 2026
$19.6MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007267 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI GARCIA-BLANCO, MARIANO A. · 1985 to 2024
$13.4MTranslating genomic discoveries to improved outcomes for high risk acute leukemiaR35CA197695 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Charles G Mullighan · 2017 to 2026
$11.4MMontefiore Academic Community NCORP ProgramUG1CA189859 · NCI · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI Balazs Halmos, Della Makower · 2014 to 2026
$10.8MNCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1 (funded extension)UG1CA232760 · NCI · MAYO CLINIC ROCHESTER · PI Judy Caroline Boughey, Aaron Scott Mansfield · 2019 to 2026
$8.5MGenomic Architecture of LGL LeukemiaR01CA178393 · NCI · UNIVERSITY OF VIRGINIA · PI Thomas P. Loughran, Aakrosh Ratan · 2016 to 2026
$6.5MMedical Scientist Training ProgramT32GM080202 · NIGMS · MEDICAL COLLEGE OF WISCONSIN · PI BARBIERI, JOSEPH T, SALZMAN, NITA H · 2010 to 2024
$5.7MDefining SMC phenotypes critical in late stage atherosclerosis pathogenesisR01HL136314 · NHLBI · UNIVERSITY OF VIRGINIA · PI OWENS, GARY K · 2018 to 2021
$3.0MNCI NIH HHS F30 CA196040NCI NIH HHS P30 CA021765NCI NIH HHS P30 CA044579NCI NIH HHS R01 CA178393NCI NIH HHS R35 CA197695NCI NIH HHS U10 CA180820NCI NIH HHS U24 CA196172NCI NIH HHS UG1 CA189859NCI NIH HHS UG1 CA232760NHLBI NIH HHS R01 HL136314NHLBI NIH HHS T32 HL007284NIGMS NIH HHS T32 GM007267NIGMS NIH HHS T32 GM080202NLM NIH HHS T32 LM012416
Abstract
Chronic lymphoproliferative disorder of natural killer cells (CLPD-NK) is characterized by clonal expansion of natural killer (NK) cells where the underlying genetic mechanisms are incompletely understood. In the present study, we report somatic mutations in the chemokine gene CCL22 as the hallmark of a distinct subset of CLPD-NK. CCL22 mutations were enriched at highly conserved residues, mutually exclusive of STAT3 mutations and associated with gene expression programs that resembled normal CD16
Indexed as
Chemokine CCL22Killer Cells, NaturalLymphoproliferative DisordersAnimalsLymphocyte ActivationMiceMutationCcl22 protein, mouseChemokine CCL22
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.